Asceneuron
PrivateLast Round
Series C
Jul 16, 2024
Total Funding Raised
$139.53M
Company Overview
Asceneuron operates in Healthcare & Life Sciences and is based in Lausanne. Its latest recorded funding round was a Series C round in July 2024.
Asceneuron is a biotechnology company that develops orally bioavailable therapeutics for neurodegenerative disorders such as Alzheimer's, Parkinson's, and orphan tauopathies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Asceneuron Comparables
Compare Asceneuron with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Treventis Corporation | 84% | |
| Alectos Therapeutics | 84% | |
| Oligomerix, Inc. | 83% |
For institutional investors. Book with your work email.
Asceneuron Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 16, 2024 | ||||
| Grant | Mar 9, 2021 | ||||
| Series A | Sep 29, 2015 | ||||
| Grant | Apr 14, 2015 | ||||
| Seed | Oct 2, 2012 |
For institutional investors. Book with your work email.
Asceneuron Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series C |
| OrbiMed | Series C |
| Novo Holdings | Series C |
| Sofinnova Partners | Series C, Series A |
| SR One | Series A, Series C |
| Johnson & Johnson Innovation - JJDC, Inc. | Series A, Series C |
| M Ventures | Series A, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 16, 2024
$100M round led by Novo Holdings.
- Sep 29, 2015
$31M round led by Sofinnova Partners.
For institutional investors. Book with your work email.
Asceneuron Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Asceneuron's valuation, stock price, and market status.
Is Asceneuron a public or private company?
Asceneuron is a private company.
What is the current stock price of Asceneuron?
Asceneuron is a private company, so its shares have no public market price. Caplight tracks Asceneuron's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Asceneuron worth (valuation)?
Valuation information for Asceneuron is not publicly available.
Can I buy Asceneuron stock?
Asceneuron shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Asceneuron's last funding round?
Asceneuron's most recent funding round was Series C on July 16, 2024.
Who are the main investors in Asceneuron?
Key investors in Asceneuron include Novo Holdings, Sofinnova Partners.
Will Asceneuron IPO soon?
No public IPO plans have been announced for Asceneuron.
How can I track Asceneuron secondary market activity?
Caplight tracks bids, offers, and trades in Asceneuron's shares on secondary markets.